Novo Nordisk challenges HC order permitting Dr Reddy's semaglutide exports

Novo Nordisk's appeal is listed for hearing on Friday before a bench of Justice C Hari Shankar and Justice Om Prakash Shukla

Danish drugmaker Novo Nordisk has launched its semaglutide-based diabetes therapy Ozempic in India, in a bid to expand its footprint in the booming glucagon-like peptide (GLP-1) market. The drug will cost ₹2,200 for a 0.25 milligram (mg) dose per week.

 

This comes just months ahead of the drug’s patent expiry in March next year.

 

Novo’s push on affordability comes as competitor Eli Lilly’s Mounjaro continues to dominate the diabetes and obesity market, as it has become the highest selling drug in India for the last two months.   

 

A once-a-week injectable GLP-1 agonist used to treat type-II diabetes, Ozempic has